Sales miss for Darzalex; cost base to expand in the forecast years
16/11/18 -"Impacted by a one-off adjustment in Europe and modest growth in the third-line and fourth-line MM setting in the US, sales for Darzalex came in below our expectations. However, given the continuous ..."
Pages
49
Language
English
Published on
16/11/18
You may also be interested by these reports :
25/03/24
Perfect execution of capacity ramp-up key for meeting targets – TP increased to CHF 81 (from CHF 75) – Reduce reiterated
21/03/24
BioNTech reported weaker than expected FY23 sales figures (-17.7%), explained by the structure of the partnering deal with Pfizer. However, investors ...
20/03/24
FDA approves TRYVIO (aprocitentan) for hypertension
19/03/24
Family controlled UCB (ADD; Belgium) has been one of the strongest performing pharma stocks (+36% in the share price) in 2024. While the recent surge ...